Luke Evnin Sells 16,310 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 16,310 shares of the stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $0.65, for a total value of $10,601.50. Following the completion of the transaction, the director directly owned 2,694,912 shares of the company’s stock, valued at $1,751,692.80. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $22,448.16.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $40,921.83.
• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $11,380.62.
• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.05, for a total transaction of $15,275.40.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $25,294.80.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total transaction of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total transaction of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total value of $39,330.24.

Werewolf Therapeutics Stock Performance

Werewolf Therapeutics stock opened at $0.61 on Wednesday. Werewolf Therapeutics, Inc. has a twelve month low of $0.56 and a twelve month high of $2.38. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $29.67 million, a P/E ratio of -0.38 and a beta of 0.74. The stock’s 50 day moving average is $1.04 and its 200 day moving average is $1.28.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. On average, equities research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HOWL has been the subject of a number of analyst reports. Zacks Research lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Wedbush downgraded shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target for the company. in a research report on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Finally, HC Wainwright decreased their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP lifted its holdings in shares of Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after buying an additional 13,439 shares during the period. MPM Bioimpact LLC increased its position in Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after acquiring an additional 20,799 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after acquiring an additional 23,852 shares during the period. MPM Asset Management LLC boosted its position in Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new position in Werewolf Therapeutics in the second quarter worth about $28,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.